The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

December 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—From 2014 through 2018, U.S. patients taking infliximab-dyyb (Inflectra) who were continuously enrolled with medical and pharmacy insurance coverage displayed a high degree of medication adherence, according to a retrospective study from Sarvesh et al.1

You Might Also Like
  • Personal Beliefs Affect Medication Adherence for RA Patients
  • Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do
  • Medication Adherence for Osteoporosis Prevention
Explore This Issue
January 2021
Also By This Author
  • Drug Updates

Using data from an IBM MarketScan commercial insurance database, researchers identified adult patients prescribed infliximab-dyyb (N=533), biosimilar to the reference product Remicade (infliximab). Patients were categorized into the following groups: infliximab-naive biosimilar users; early switchers, who had used the reference product for less than two years; and late switchers, who had used the reference product long term (i.e., more than two years).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The first prescription filled for infliximab-dyyb was the study’s index date, with the baseline defined as 365 days prior to this date. The follow-up period started on the index date and ran through the earliest death date, loss of health insurance coverage date or Dec. 31, 2018. All patients’ baseline characteristics were evaluated, as well as the proportion of days covered at 12 months of follow-up. The proportion of days patients received medication refills categorized the medication adherence level and was broken down further as less than 50%, 50–80% and greater than 80%.

The Data
In the study, 98 patients were infliximab-naive biosimilar users, 114 were early switchers and 113 were late switchers. Infliximab-naive biosimilar users tended to be younger and female. Most patients had inflammatory bowel disease (41–45%), rheumatoid arthritis (15–30%) or psoriasis (10–14%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Adherence for patients who had more than 12 months follow-up were: 54% of infliximab-naive biosimilar users, 44% of early switchers and 56% of late switchers. The adjusted odds ratio for high adherence among infliximab-naive biosimilar users was 1.68 (P=0.26) and 0.70 (P=0.35) for early switchers, meaning the former group was more likely to adhere to biosimilar treatment than the latter.

This study showed about half the patients were highly adherent to biosimilar treatment use at month 12 of treatment. Further studies are needed to assess long-term adherence to infliximab-based biosimilars.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Sarvesh S, Alanaeme J, Curtis J, et al. Utilization and adherence among infliximab biosimilar initiators in a U.S. National Commercial Insurance Database (abstract: 0555). Arthritis Rheumatol. 2020 Oct; 72(suppl 10).

Filed Under: ACR Convergence, Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, adherence, INFLECTRA (infliximab-dyyb), infliximab-dyybIssue: January 2021

You Might Also Like:
  • Personal Beliefs Affect Medication Adherence for RA Patients
  • Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do
  • Medication Adherence for Osteoporosis Prevention
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.